Placebo matching Dapagliflozin

DRUG5 trials

Sponsors

Universitaetsklinikum Tuebingen AöR, AstraZeneca, University Hospital Tuebingen

Conditions

Type 1 Diabetes MellitusType 2 DiabetesType 2 Diabetes Mellitus (T2DM)early stage of chronic kidney disease (CKD stage G1A2/G2A2) and prediabetes

Phase 2

BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes

CompletedNCT01498185

AstraZenecaType 1 Diabetes Mellitus

Start: 2012-02-29End: 2012-10-31Updated: 2017-02-10

Phase 3

Add-on to Thiazolidinedione (TZD) Failures

CompletedNCT00683878

AstraZenecaType 2 Diabetes

Start: 2008-07-31End: 2010-06-30Updated: 2017-02-23

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

CompletedNCT01195662

AstraZenecaType 2 Diabetes

Start: 2010-10-31End: 2013-02-28Updated: 2016-12-29

Phase 4

Dapagliflozin Effect on Erythropoiesis and Physical Fitness

WithdrawnNCT03423355

University Hospital TuebingenType 2 Diabetes Mellitus (T2DM)

Start: 2021-09-30End: 2023-12-31Updated: 2021-12-15

SGLT2 inhibition in addition to lifestyle intervention and risk for complications in subtypes of patients with prediabetes - a randomized, placebo controlled, multi-center trial

RecruitingCTIS2024-512179-11-00

Universitaetsklinikum Tuebingen AöRearly stage of chronic kidney disease (CKD stage G1A2/G2A2) and prediabetes

Start: 2023-10-26Target: 182Updated: 2025-05-22

Related Papers

Effectiveness of dapagliflozin as an insulin adjunct in type 1 diabetes: a semi-mechanistic exposure-response model

Frontiers in Pharmacology2023-10-25

Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus

The Journal of Clinical Pharmacology2022-04-117 citations

A model‐based approach to investigating the relationship between glucose‐insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes

Diabetes Obesity and Metabolism2020-12-248 citations

Model‐based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus

Diabetes Obesity and Metabolism2019-02-139 citations

Dapagliflozin Exposure Response in Japanese vs. Non-Japanese Patients with Type 1 Diabetes

Diabetes2018-06-221 citations

Hypersensitivity Events, Including Potentially Hypersensitivity-Related Skin Events, with Dapagliflozin in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.

2016-11-0114 citations

The effect of dapagliflozin on renal function in patients with type 2 diabetes

Journal of Nephrology2016-02-1977 citations

Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.

2015-11-27174 citations